One night of a sleep study is the standard for diagnosis and exclusion of obstructive sleep apnea. Single testing requires high sensitivity of the test method and a stable disease of interest to warrant a low rate of falsenegative tests. Obstructive sleep apnea is diagnosed and graded by conventional thresholds of apneas and hypopneas per hour of sleep, and treatment is usually initiated in the presence of symptoms. The aim of this study was to assess night-to-night variability of obstructive sleep apnea to reassess the current practice. Seventy-seven patients previously diagnosed with obstructive sleep apnea, randomised to continuous positive airway pressure withdrawal within four trials, performed nightly pulse-oximetry over 2 weeks while off continuous positive airway pressure. The main outcome of interest was the coefficient of variation of the oxygen desaturation index marking night-to-night variability in obstructive sleep apnea. Obstructive sleep apnea was categorised according to conventional thresholds using oxygen desaturation index (no obstructive sleep apnea: <5 per h; mild: 5-15 per h; moderate: 15-30 per h; and severe: >30 per h). High night-to-night variability of obstructive sleep apnea was evidenced by a coefficient of variation of oxygen desaturation index of 31.1% (SD 16.5) . Differences in oxygen desaturation index of >10 per h between nights were found in 84.4% and shifts in obstructive sleep apnea severity category in 77.9% of patients. The probability of missing moderate obstructive sleep apnea was up to 60%. Variability was higher in less severe obstructive sleep apnea. Obstructive sleep apnea shows a considerable night-to-night variability. Single-night diagnostic sleep studies are prone to miscategorise obstructive sleep apnea if arbitrary thresholds are used. Thus, treatment decisions should be based less on the conventional derivatives from sleep studies, especially in patients with less severe obstructive sleep apnea. Clinical trial registration: www.controlled-trials.com (ISRCTN 93153804, ISRCTN 73047833) and www.clinicaltrials.gov (NCT01332175 & NCT02050425).
IN TROD UCTI ON
Obstructive sleep apnea (OSA) is a common sleep-related breathing disorder with an estimated prevalence of symptomatic OSA of 2-4% of the adult population in Western countries that has substantially increased during the last two decades, and a considerable percentage of the population seems to be affected but not diagnosed (Peppard et al., 2013; Young et al., 1993 Young et al., , 1997 .
As a disease entity, OSA is characterised by repetitive obstructions of the upper airway during sleep, resulting in apneas and hypopneas, usually causing oxygen desaturation, increased inspiratory effort, brief arousals and sleep disturbances (Jenkinson et al., 1999; Sateia, 2014) . As a consequence, untreated patients suffer from daytime sleepiness, an increased risk of motor vehicle accidents, cardiovascular disease, and an impaired quality of life (George, 2001; Jenkinson et al., 1999; Kohler et al., 2008) . Currently, the gold-standard diagnostic test for OSA advocated in some guidelines is in-laboratory polysomnography (PSG; Berry et al., 2012) . This method is relatively costly, time-consuming and technically complex (Collop et al., 2007; Kim et al., 2015) . Alternatively, in patients with a high pre-test probability for moderate-to-severe OSA based on clinical evaluation and no relevant co-morbidity, portable home devices can be utilised with sufficient accuracy (Collop et al., 2007) . Also, overnight pulse-oximetry is an appealing method to diagnose OSA, because of its widespread availability and accurate estimation of OSA severity (Stradling et al., 2003; Vazquez et al., 2000; Whitelaw et al., 2005) .
The current guidelines recommend a single full-night in-laboratory sleep study or a home sleep study with a portable monitor for diagnosis of OSA with a threshold >15 obstructive events per h of sleep, or >5 obstructive events per h plus clinical symptoms, to diagnose OSA (Epstein et al., 2009) . Single testing requires high sensitivity of the test method and a stable disease of interest to warrant a low rate of false-negative tests. The current guidelines presuppose that the number of obstructive events is consistent on consecutive nights. However, considerable variability on repeated measurements has been found (Aarab et al., 2009; Levendowski et al., 2009; White et al., 2015) . Especially in patients with mild OSA, nightto-night variability may lead to misdiagnosis, as there are often false-negative sleep studies in such patients (Dean and Chaudhary, 1992) . A factor proposed to be accountable for varying scores of the apnea-hypopnea index (AHI) is the firstnight effect due to a lower total sleep time, a reduction in quantity of rapid eye movement (REM) sleep, more intermittent wake time and longer REMs latency in the first night of inlaboratory PSG (Le Bon et al., 2000; Ma et al., 2011) . However, studies observing more than two consecutive nights show sustained intra-individual alterations of OSA severity with only consistent mean values in the overall study population (Bittencourt et al., 2001; Chediak et al., 1996) . As previous studies were limited by small study populations and study durations of only a few sequential nights, the aim of our study was to assess night-to-night variability of disease severity in patients with known OSA using nocturnal oximetry in an accustomed environment over 2 weeks to assess the reliability of the current practice of diagnosing OSA based on sleep monitoring for 1 night only.
MATERI ALS AND METHODS

Trial design and intervention
All patients with OSA included in the current analysis were previously treated with continuous positive airway pressure (CPAP) and took part in one of four parallel-group randomised controlled CPAP-withdrawal trials. They were randomly assigned to either continue therapeutic CPAP or to withdraw CPAP [sub-therapeutic CPAP or non-therapeutic nasal expiratory positive airway pressure (EPAP) device] after a baseline in-laboratory sleep study on therapeutic CPAP (Kohler et al., 2011; Rossi et al., 2013; Schwarz et al., 2016; Stradling et al., 2015) . Patients performed nightly pulse-oximetry before returning for a follow-up in-laboratory sleep study at 2 weeks. More details and eligibility criteria are presented in the online supplements.
Randomisation and blinding
All patients were blinded regarding their treatment allocation. Randomisation and blinding have previously been reported (Kohler et al., 2011; Rossi et al., 2013; Schwarz et al., 2016; Stradling et al., 2015) .
Participants
One-hundred and ninety-seven patients previously diagnosed with OSA and effectively treated with CPAP, participating in four randomised controlled CPAP-withdrawal trials (Kohler et al., 2011; Rossi et al., 2013; Schwarz et al., 2016; Stradling et al., 2015) , were randomly assigned to either continue therapeutic CPAP (n = 88) or to withdraw CPAP (n = 109) by either a sham-CPAP device (60%) or an ineffective nasal EPAP device (40%), depending on the specific protocol. The difference in the participant numbers between the two arms is due to three treatment groups (two of which correspond to a CPAP therapy withdrawal) in one of the original trials (Rossi et al., 2013) . For the current study, only patients allocated to CPAP-withdrawal, and thus having a recurrence of OSA, were analysed. Eligibility criteria are given in the online supplementary information.
Outcomes
The main outcome of interest was the coefficient of variation (CV) of the oxygen desaturation index (ODI; ≥4% dips per h) as a measure of variability of OSA severity during 2 weeks of CPAP-withdrawal.
Other outcomes of interest were the change in OSA severity categories (according to conventional ODI thresholds: no OSA: <5 per h; mild: 5-15 per h; moderate: 15-30 per h; severe: >30 per h) between different nights, maximal differences in ODI between nights, probability of misdiagnosis of OSA and potential predictors of night-to-night variability of OSA. The first night of CPAP-withdrawal was excluded from the analysis, taking into account the time needed for a complete recurrence of OSA (Kohler et al., 2011) .
Measurements
Nightly pulse-oximetry was performed using a wrist-worn finger pulse-oximeter with internal memory capable of storing ª 2017 European Sleep Research Society at least 14 nights of data (Pulsox-300i; Konica-MinoltaSensing, Osaka, Japan) or ResLink (ResMed-Corp, San Diego, CA, USA) at home. Patients were instructed to activate the pulse-oximeter at the time of going to sleep each night of the 2-week study period. For further details, see Data S1.
Statistical methods
Results are shown as mean with standard deviation unless otherwise stated. The CV of the ODI from day 2 to day 13 of CPAP-withdrawal was calculated in each participant. Patients were categorised in the subsequent ways, depending on their mean, highest and lowest ODI during the study period, as having no (ODI <5 per h), mild (≥5 per h ODI <15 per h), moderate (≥15per h ODI <30 per h) or severe OSA (ODI ≥30 per h), respectively.
Univariate and multivariate regression analysis was used to investigate associations between the CV of ODI and possible predictors of the night-to-night variability. A non-linear association between the CV and possible predictors was considered, including the logarithmic term of CV in the analysis. The probability of incorrectly categorising moderate or severe OSA as either normal or mild (mean ODI <15 per h) based on a single-night oximetry was calculated. For detailed statistical methods, see Data S1.
Statistical analysis was performed with STATA 14 (StataCorp, College Station, TX, USA).
RESUL TS Participants
Within the original four randomised controlled trials, 109 previously optimally CPAP-adherent patients with OSA were randomised to CPAP-withdrawal. Four patients dropped out of the study and 28 patients did not perform nocturnal pulseoximetry. Thus, complete pulse-oximetry data over the study period were available from 77 patients. These 77 patients entered the final analysis. The patient flow is shown in Fig. 1 . Baseline characteristics of the participants are shown in Table 1 .
Course of ODI during 2 weeks
Patients underwent nocturnal pulse-oximetry for 13 nights of CPAP-withdrawal. The mean ODI at baseline on CPAP was 3.5 per h (4.4). In response to CPAP-withdrawal, the ODI (group mean) increased to 22.1 per h (17.4) on night 1 and plateaued thereafter, as shown in Fig. S1 . A full return of OSA was therefore assumed on the second night of therapywithdrawal, and night-to-night variability was analysed from day 2 to 13 of CPAP-withdrawal. Figure S2 exemplarily shows the ODI over the study period in eight different patients.
Night-to-night-variability in ODI
A considerable night-to-night variability in OSA severity throughout the study period was found. The CV of ODI was 31.1% (16.5), as shown in Table 2 and visualised in Fig. S3 .
When categorizing OSA severity depending on the patients' highest and lowest ODI throughout the study period, 78% of patients switched between clinical categories of OSA severity. Only 22% of participants remained in the same category throughout the study period, while 52% changed by one category, 25% changed to the extent of two categories, and one participant even switched between three categories (no versus severe OSA). When using the highest ODI during the study period, 62% of patients were diagnosed with severe OSA, whereas only 16% of patients had severe OSA if the night with the lowest ODI was considered (Fig. 2) ; 62.3% of participants had maximal differences in ODI between different nights of 10-30 per h. A difference of less than 10 per h between nights was observed in only 15.6% of patients.
Clinical predictors of night-to-night variability
In univariate regression analysis, ODI off CPAP in the pretrial screening, ODI at diagnosis and body mass index (BMI) on the day of the baseline sleep study showed a statistically significant negative association with the log CV (Table S1 ). Multivariable regression analysis including BMI and ODI off CPAP from the pre-trial screening showed an independent negative association between OSA severity and night-tonight variability (Table 3) . However, the model explained the variability only to a small extent. The ODI at diagnosis was removed from the model due to a high inter-relationship with ODI off CPAP from the pre-trial screening (r = 0.56, P < 0.001). Residual analysis of the final model did not display any violation of the regression assumptions. OSA severity remained a statistically significant negative predictor of night-to-night variability after correcting for age and gender, i.e. there is less night-to-night variation as the ODI rises.
Probability of underestimating the severity of OSA The probability of measuring an ODI <15 per h in at least 1 night in patients with moderate or severe OSA (ODI >15 per h) based on mean ODI over 2 weeks was estimated to be up to 60% in patients with moderate OSA and up to 10% in patients with severe OSA (Fig. 3) . Only patients with a mean ODI >40 per h were consistently diagnosed each night with at least moderate OSA (ODI >15 per h).
DISCUSSION
Two weeks of nocturnal pulse-oximetry in patients with OSA during CPAP therapy withdrawal have demonstrated considerable night-to-night variability of OSA with a CV of ODI of >30%. OSA of moderate severity would have been missed with a probability of up to 60% in at least 1 night of nocturnal oximetry. Only 22% of participants -primarily patients with severe OSA -did not change severity group, whereas more than three-quarters of patients switched between conventional severity categories. The findings of our study implicate the necessity to reconsider current diagnostic algorithms and treatment decisions in patients with OSA as well as of conventional severity thresholds of OSA. Patients with mild OSA seem to have a higher night-to-night variability than patients with severe OSA, leading to the conclusion that single-night diagnostic sleep studies are prone to miss OSA in patients with milder disease and that repeated measurements will help to improve patient categorisation and thus treatment decision making. Two-3 nights of repeated sleep studies in different patient populations have previously demonstrated differences in measures of OSA severity, such as AHI or ODI, but to a lesser extent (Ahmadi et al., 2009; Bittencourt et al., 2001; Chediak et al., 1996; Dean and Chaudhary, 1992; Levendowski et al., 2009; White et al., 2015) . Moreover, intra-individual variability occurred in repeated measurements 3 weeks apart (Aarab et al., 2009) . Other authors also reported categorical changes in 40-50% of patients during 2-4 nights of sleep monitoring (Bittencourt et al., 2001; Mosko et al., 1988; Newell et al., 2012) . Severity category changes between no/mild and moderate OSA (AHI or ODI ≥15 per h) seem clinically relevant, as in some centres patients with mild disease are less likely to be treated. In our study population, the possibility of an ODI <15 per h in a random night was up to 60% in patients with moderate OSA (ODI 15-30 per h) and up to 10% in patients with severe OSA (ODI >30 per h) based on the mean ODI over 12 nights, respectively. Only patients with a mean ODI >40 per h over 2 weeks were categorised as having at least moderate OSA (ODI >15 per h) in each individual night. In comparison to previous studies, our findings show a higher probability of underestimating OSA. Other authors stated that 16-20% of patients would not have received CPAP treatment based on a single-night sleep study, but were recommended treatment as a consequence of one-three repeated sleep studies (Ahmadi et al., 2009; Lord et al., 1991; Newell et al., 2012) . Comparing the distribution of OSA severity categories between the night with the lowest and the highest ODI in this study, the percentage of patients diagnosed with moderate to severe OSA doubled from 44 to 87% or, in other words, the percentage of patients diagnosed with no/only mild OSA decreased from 56 to 13%. A lower variability in AHI was reported in the largest study on variability of sleepdisordered breathing based on three consecutive nights of portable home sleep monitoring, with only 10% of patients changing between no/mild and moderate OSA (Stepnowsky et al., 2004) . When using the same approach and analysing only the first 3 nights in the current study, 18.2% of patients changed category based on a threshold of ODI of 15 per h, compared with 42.9% when including all nights. In accordance with our finding, Le Bon et al. (2000) and Ward et al. (2015) reported a higher variability in AHI in mild to moderate compared with severe OSA.
The high variability of OSA may be pathophysiologically explained by the nature of OSA. Most patients show alternating episodes of stable breathing and episodes of obstructive apneas and hypopneas during the course of a night. Baseline upper airway dilator tone and the effectiveness of mechanisms counteracting upper airway collapse vary during sleep (Younes, 2003) . The most important influencing factors are sleep stage and sleep position, whereby supine position and REM sleep facilitate upper airway collapse as well as intake of alcohol and sedatives (Ahmadi et al., 2009; Joosten et al., 2014; Shea et al., 1999; Younes, 2003) . It may be assumed that our participants' sleep positions and sleep stages differed between nights, therefore, affecting the severity of OSA each night differently. However, although there are data on variability over 2 nights, to our knowledge there are no reliable data on the variability of sleep positions and stages over several nights (Joosten et al., 2014) .
The current study has some limitations. Because we did not use PSG, the impact of sleep stage and position on OSA remains unknown. However, nocturnal finger pulse-oximetry is more suitable to study the natural course of disease severity in patients with known OSA due to minimal interference with sleep quality in patients' home environment compared with a level I or in-laboratory sleep study. Moreover, looking at available data in 64 patients during respiratory polygraphy at baseline and comparing interchangeability of AHI and ODI values for calculating severity categories shows categorical differences in merely eight patients (12.5%). This study's findings have important clinical implications. A single-night level I sleep study is currently the gold-standard for evaluating sleep-disordered breathing. The high possibility we found of seeing an ODI <15 per h on a random night, in patients with a mean ODI >15 per h over the study period, makes the current practice of basing clinical decisions on relatively arbitrary and unstable thresholds questionable. The results of this study imply the need for repeated sleep studies in diagnostic algorithms in the case of a negative sleep study in patients with high suspicion of OSA. Repeated measurements decrease the likelihood of mis-categorisation and thus allow more confident treatment recommendations in patients with OSA.
CONCLUSI ON S
The severity of OSA seems to vary considerably from night to night. Single-night diagnostic sleep studies are prone to miscategorise the severity of OSA, especially when arbitrary thresholds are used for clinical purposes. Thus, treatment decisions should be based on either prolonged sleep studies, more on the clinical history, or on actual therapeutic trials of CPAP, especially in milder OSA and in minimally symptomatic patients, as these patients may also benefit from long-term treatment. 
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Data S1. Supplementary methods Figure S1 . The course of the oxygen desaturation index (ODI) in the study population over 14 days is illustrated. Figure S2 . The course of the oxygen desaturation index (ODI) over the two-week study period is shown in four exemplary participants. Figure S3 . Spread of the coefficient of variation of the oxygen desaturation index. Table S1 . Possible predictors of the log coefficient of variation of ODI (univariate regression).
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